Related Experiment Video
Updated: Jun 10, 2025
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor
Mobina Tabibian1, Fahimeh Salasar Moghaddam2, Elahe Motevaseli3
1Department of Cellular and Molecular Biology, Faculty of Life Sciences and Biotechnologies, Shahid Beheshti University, Tehran, Iran.
Background:
Prostate cancer is among prevalent cancers in men. Numerous strategies have been proposed to intervene with the important prostate cancer-related signaling pathways. Among the most promising strategies is CRISPR/Cas9 strategy. This strategy has been used to modify expression of a number of genes in prostate cancer cells.
Aims:
This review summarizes the most recent progresses in the application of CRISPR/Cas9 strategy in modification of prostate cancer-related phenotypes with an especial focus on pathways related to androgen receptor signaling.
Conclusion:
CRISPR/Cas9 technology has successfully targeted several genes in the prostate cancer cells. Moreover, the efficiency of this technique in reducing tumor burden has been tested in animal models of prostate cancer. Most of targeted genes have been related with the androgen receptor signaling. Targeted modulation of these genes have affected growth of castration-resistant prostate cancer. PI3K/AKT/mTOR signaling and immune response-related genes have been other targets that have been successfully modulated by CRISPR/Cas9 technology in prostate cancer. Based on the rapid translation of this technology into the clinical application, it is anticipated that novel treatments based on this technique change the outcome of this malignancy in future.
Insights
CRISPR/Cas9 technology shows promise for prostate cancer treatment by modifying key genes, including those in androgen receptor signaling. This gene-editing tool has demonstrated effectiveness in reducing tumor burden in preclinical models.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Prostate cancer is a prevalent malignancy in men.
- Gene signaling pathways are critical in prostate cancer progression.
- CRISPR/Cas9 gene editing offers a novel therapeutic strategy.
Purpose of the Study:
- To review recent advancements in CRISPR/Cas9 applications for prostate cancer.
- To focus on the modification of androgen receptor signaling pathways.
- To highlight CRISPR/Cas9's role in altering prostate cancer phenotypes.
Main Methods:
- CRISPR/Cas9 gene editing was employed to modify gene expression in prostate cancer cells.
- Targeted genes were analyzed for their role in prostate cancer phenotypes.
- Efficacy was assessed in preclinical animal models of prostate cancer.
Main Results:
- CRISPR/Cas9 successfully targeted multiple genes in prostate cancer cells.
- Modulation of androgen receptor signaling genes impacted castration-resistant prostate cancer growth.
- PI3K/AKT/mTOR and immune response genes were also modulated effectively.
Conclusions:
- CRISPR/Cas9 technology has proven effective in targeting critical genes in prostate cancer.
- Preclinical studies show potential for reducing tumor burden.
- Future clinical applications of CRISPR/Cas9 may significantly alter prostate cancer outcomes.
